These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 25449964)

  • 1. Case report of thrombotic microangiopathy associated with subcutaneous interferon beta-1a: an emerging complication?
    Azkune Calle I; Sánchez Menoyo JL; Ruiz Ojeda J; García Moncó JC; Etxeguren Urkixo I
    Neurologia; 2016 Sep; 31(7):508-9. PubMed ID: 25449964
    [No Abstract]   [Full Text] [Related]  

  • 2. The Case | The young philosopher with multiple sclerosis and proteinuria.
    Piccoli GB; Capobianco M; Vigotti FN; Naretto C; Narioz C; Brocheriou I; Roccatello D
    Kidney Int; 2016 Apr; 89(4):961-3. PubMed ID: 26994580
    [No Abstract]   [Full Text] [Related]  

  • 3. Cumulative Review of Thrombotic Microangiopathy, Thrombotic Thrombocytopenic Purpura, and Hemolytic Uremic Syndrome Reports with Subcutaneous Interferon β-1a.
    Ben-Amor AF; Trochanov A; Fischer TZ
    Adv Ther; 2015 May; 32(5):445-54. PubMed ID: 25991578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term efficacy and safety of intramuscular interferon beta-1a: Randomized postmarketing trial of two dosing regimens in Japanese patients with relapsing-remitting multiple sclerosis.
    Saida T; Kira J; Ueno Y; Harada N; Hirakata T
    Mult Scler Relat Disord; 2016 May; 7():102-8. PubMed ID: 27237769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Favorable outcome of interferon-beta associated thrombotic microangiopathy following treatment with corticosteroids, plasma exchange and rituximab: A case report.
    Gerischer LM; Siebert E; Janke O; Jungehuelsing GJ; Ruprecht K
    Mult Scler Relat Disord; 2016 Nov; 10():63-65. PubMed ID: 27919500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal thrombotic microangiopathy caused by interferon beta-1a treatment for multiple sclerosis.
    Mahe J; Meurette A; Moreau A; Vercel C; Jolliet P
    Drug Des Devel Ther; 2013; 7():723-8. PubMed ID: 23950639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between Interferon Beta-1A Administration and Intracranial Vascular Tone Regulation in Patients with Relapsing-Remitting Multiple Sclerosis: A Pilot Study.
    Dattola V; Bonanno L; Naro A; Chillura A; Logiudice AL; Sessa E; Famà F; Quartarone A; Calabrò RS; Marino S; Russo M
    Biomed Res Int; 2017; 2017():5421416. PubMed ID: 29057262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombotic Microangiopathy Presenting with Intestinal Involvement Following Long-term Interferon-β1b Treatment for Multiple Sclerosis.
    Omoto S; Utsumi T; Matsuno H; Terasawa Y; Iguchi Y
    Intern Med; 2018 Mar; 57(5):741-744. PubMed ID: 29151517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Necrotizing Fasciitis in a Patient on Long-Term Intramuscular Interferon-Beta for Multiple Sclerosis: A Case Report.
    McDaniel C; Trankiem C
    JBJS Case Connect; 2020; 10(1):e0288. PubMed ID: 32224665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon Beta-1a (AVONEX®) as a Treatment Option for Untreated Patients with Multiple Sclerosis (AXIOM): A Prospective, Observational Study.
    Kleinschnitz C; Niemczyk G; Rehberg-Weber K; Wernsdörfer C
    Int J Mol Sci; 2015 Jul; 16(7):15271-86. PubMed ID: 26154767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Administration of subcutaneous interferon beta 1a in the evening: data from RELIEF study.
    Patti F; Zimatore GB; Brescia Morra V; Aguglia U; Bossio RB; Marziolo R; Valentino P; Chisari CG; Capacchione A; Zappia M;
    J Neurol; 2020 Jun; 267(6):1812-1823. PubMed ID: 32140867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rhabdomyolysis following interferon-beta treatment in a patient with multiple sclerosis - A case report.
    Dalbjerg SM; Tsakiri A; Frederiksen JL
    Mult Scler Relat Disord; 2016 Jul; 8():93-5. PubMed ID: 27456881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quality of life, depression and fatigue in mildly disabled patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: 3-year results from the COGIMUS (COGnitive Impairment in MUltiple Sclerosis) study.
    Patti F; Amato MP; Trojano M; Bastianello S; Tola MR; Picconi O; Cilia S; Cottone S; Centonze D; Gasperini C;
    Mult Scler; 2011 Aug; 17(8):991-1001. PubMed ID: 21502310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of peginterferon beta-1a compared with interferon beta-1a and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis in the United States.
    Hernandez L; Guo S; Kinter E; Fay M
    J Med Econ; 2016 Jul; 19(7):684-95. PubMed ID: 26947984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon beta-related nephropathy and interstitial lung disease: a new association and a long-term warning.
    Capobianco M; Piccoli G; Neve Vigotti F; Scapoli P; Deagostini MC; Albera C; Roccatello D; Bertolotto A
    Mult Scler; 2014 Jun; 20(7):889-91. PubMed ID: 24446386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Interferons beta in patients with multiple sclerosis].
    Vlasov IaV; Kuznetsova NI; Poverennova IE; Khivintseva EV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2005; 105(7):54-5. PubMed ID: 16117149
    [No Abstract]   [Full Text] [Related]  

  • 17. Impact of daclizumab versus interferon beta-1a on patient-reported outcomes in relapsing-remitting multiple sclerosis.
    Liu Y; Vollmer T; Havrdova E; Riester K; Lee A; Phillips G; Wang P; Sabatella G
    Mult Scler Relat Disord; 2017 Jan; 11():18-24. PubMed ID: 28104250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Retinopathy secondary to treatment with Interferon beta-1a in a patient with multiple sclerosis].
    Mallada-Frechín J; Abellán-Miralles I; Alfaro-Beltra ML; Medrano V; Muñoz-Gil MB; Fernández-Izquierdo S; Piqueras-Rodríguez L
    Rev Neurol; 2005 Apr 16-30; 40(8):482-4. PubMed ID: 15861330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term persistence with injectable therapy in relapsing-remitting multiple sclerosis: an 18-year observational cohort study.
    Zhornitsky S; Greenfield J; Koch MW; Patten SB; Harris C; Wall W; Alikhani K; Burton J; Busche K; Costello F; Davenport JW; Jarvis SE; Lavarato D; Parpal H; Patry DG; Yeung M; Metz LM
    PLoS One; 2015; 10(4):e0123824. PubMed ID: 25867095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acquired factor VIII inhibitor in a patient with multiple sclerosis treated with interferon β-1a.
    Pandya D; Hellerslia V; Gettings E
    J Neuroimmunol; 2020 Mar; 340():577146. PubMed ID: 31945592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.